Compare Ryanair Holdings plc (RYAAY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Vertex Pharmaceuticals Incorporated — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.2× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays a 1.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| RYAAY | VRTX | |
|---|---|---|
Market Cap | $29.31B | $121.95B |
Sector | Industrials | Health |
52-Week High | $73.82 | $529.59 |
52-Week Low | $53.24 | $366.54 |
Enterprise Value | $26.33B | $116.69B |
Dividend Yield | 1.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
